title: Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kaul
authors.forename: Ann F
authors.initials: AF
authors.lastname: Bolger
authors.forename: David
authors.initials: D
authors.lastname: Herrington
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
authors.forename: Robert H
authors.initials: RH
authors.lastname: Eckel
mesh_terms: D026683:Advisory Committees; D000572:American Heart Association; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000453:epidemiology*; D015995:Prevalence; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone